-
Worg Pharmaceuticals Secures Major Financing for Allergy and Autoimmune Disease Therapies
•
Worg Pharmaceuticals (Zhejiang) Co., Ltd., a China-based biopharmaceutical company specializing in the development of immunotherapies for allergic and autoimmune diseases, has successfully raised hundreds of millions of renminbi in a new financing round. The round saw participation from notable investors such as PICC Investment, Tsing Song Capital, and an undisclosed…
-
Worg Pharmaceuticals Gets FDA Approval for Phase II Graves’ Disease Study
•
Worg Pharmaceuticals, a Hangzhou-based developer of allergic drugs, has received the green light from the US Food and Drug Administration (FDA) to proceed with a Phase II clinical study for its drug candidate WP1302 in the treatment of Graves’ disease. Graves’ disease, a prevalent autoimmune condition, impacts an estimated 10…
-
Worg Pharmaceuticals Expands into Spain with Acquisition of Diater for EUR 150 Million
•
Worg Pharmaceuticals, a Hangzhou-based developer of allergic drugs, has formally entered the Spanish market by obtaining the necessary regulatory approval and completing the acquisition of local biopharmaceutical company Diater from fund manager Nazca Capital for approximately EUR 150 million (USD 160 million). This strategic move marks a significant expansion for…
